{"analyses":[{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.79","groupDescription":"At CCOD 18 months; Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein (AFP: \\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0006","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","groupDescription":"At CCOD 30 months; Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein (AFP: \\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0009","paramType":"Hazard Ratio (HR)","paramValue":"0.66","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"10.41","upperLimit":"NA","value":"13.24"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"At CCOD 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.37","upperLimit":"16.85","value":"13.40"},{"groupId":"OG001","lowerLimit":"17.02","upperLimit":"23.66","value":"19.22"}]}],"title":"At CCOD 30 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEDIAN","populationDescription":"Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)","title":"Overall Survival (OS) in the Global Population","type":"PRIMARY","unitOfMeasure":"months"}